Advaxis Inc: Jumps on positive early data from lung cancer treatment study

Ayala Pharmaceuticals

20/05/2021 11:36

** Shares of the biotech co  ADXS.O  rise 8.8% to 63 cents
in premarket trade
    ** Co on Wednesday reported updated data from its ongoing
early-stage study of a combination therapy for lung cancer
 urn:newsml:reuters.com:*:nGNXSxtZt
    ** Says updated data shows its drug ADXS-503, when used as
an add-on therapy with Merck's  MRK.N  Keytruda for patients
with non-small cell lung carcinoma, resulted in a disease
control rate of 44%
    ** Co says it also noted durable clinical benefit beyond one
year in patients 
    ** Results suggest ADXS-503 may be an important new
off-the-shelf immunotherapy treatment option - CEO Ken Berlin
    ** ADXS stock up about 65% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))